Patient Access & Affordability
  • About
    • Mission
    • Who We Are
    • Advisory Board
    • Patient Advisors
    • Members
    • Funding
    • Contact
  • Resources
    • Blog
    • Watch & Listen
    • Surveys
  • Publications
    • Research Briefings
    • Current Issues
    • Fast Facts
    • Policy Platform
  • Working Groups
    • Benefit Design
    • Rare Disease Health Technology Assessment
      • Featured Work
    • Biosimilars & Complex Generics
  • ICERWATCH
    • What is ICER?
    • ICER Glossary
    • Analysis and Commentary
    • Public Comments
Select Page
Institute for Patient Access & Affordability Comments on ICER Oral Semaglutide for Type 2 Diabetes: Draft Evidence Report

Institute for Patient Access & Affordability Comments on ICER Oral Semaglutide for Type 2 Diabetes: Draft Evidence Report

Oct 19, 2019

Institute for Patient Access & Affordability (IPAA) is a new program division of Patients Rising with the mission to provide patient-powered pathways to help both public and private payers as they make critical coverage decisions for patients with rare and chronic...

Categories

  • Access & Affordability
  • Blog
  • Comments
  • ICERWatch
  • News
  • Opinion
  • QALY
  • Research
  • Resources
  • Statements
  • Uncategorized
  • Video

IPAA

700 12th St. NW, Suite 700
Washington, DC 20005
202-750-1186 |  info@accessandaffordability.org

The Patient Access & Affordability Project is a program of Patients Rising, a national 501(c)3 nonprofit organization, and is governed by the Patients Rising Board of Directors.

  • Facebook
  • Twitter
  • RSS